PT - JOURNAL ARTICLE AU - G.Y. Lam AU - J. Goodwin AU - P.G. Wilcox AU - B.S. Quon TI - Sex Disparities in Cystic Fibrosis: Review on the Effect of Female Sex Hormones on Lung Pathophysiology and Outcomes AID - 10.1183/23120541.00475-2020 DP - 2020 Jan 01 TA - ERJ Open Research PG - 00475-2020 4099 - http://openres.ersjournals.com/content/early/2020/10/15/23120541.00475-2020.short 4100 - http://openres.ersjournals.com/content/early/2020/10/15/23120541.00475-2020.full AB - Sex differences in morbidity and mortality have been reported in the cystic fibrosis (CF) population worldwide. However, it is unclear why CF women have worse clinical outcomes than men. In this review, we focus on the influence of female sex hormones on CF pulmonary outcomes and summarise data from in vitro and in vivo experiments on how estrogen and progesterone might modify mucociliary clearance, immunity and infection in the CF airways. The potential for novel sex hormone related therapeutic interventions is also discussed.FootnotesThis manuscript has recently been accepted for publication in the ERJ Open Research. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJOR online. Please open or download the PDF to view this article.Conflict of interest: Dr. Lam has nothing to disclose.Conflict of interest: Dr. Goodwin has nothing to disclose.Conflict of interest: Dr. Wilcox has nothing to disclose.Conflict of interest: B.S. Quon reports speaker fees from Vertex Pharmaceuticals, advisory board fees from Proteostasis Therapeutics, and grants from CF Canada, the CF Foundation, Gilead Sciences and the BC Lung Association, outside the submitted work.